CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
Zafirlukastdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04339140
NCT04339140Phase 2Completed
CompareCT.gov

A Phase 2 Study of Zafirlukast for the Treatment of Tumor-marker Only Relapsed Ovarian Cancer

Beth Israel Deaconess Medical Center·interventional·Posted Apr 9, 2020·Updated Dec 11, 2025

In Brief

A Phase 2 clinical trial evaluating Zafirlukast for Ovarian Cancer. Completed, enrolled 5 participants across 1 site.

Detailed Summary

This research study is evaluating the effectiveness of Zafirlukast to prevent tumor activity in participants with tumor marker-only relapsed ovarian cancer. * The name of the study drug involved in this study is: * Zafirlukast

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Cancer Institute (NCI), Dana-Farber Cancer Institute

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 9, 2020
Enrollment StartJun 24, 2020
Primary CompletionDec 31, 2023
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 6.2 years ago

Interventions

Zafirlukastdrug

Oral tablets, 2x daily for 28 day cycle up to 1 year